Purple Biotech Q3 net loss narrows 25% to USD 981,000
PPBT•Purple Biotech’s third-quarter 2026 net loss narrowed 25% year over year to USD 981,000. Cash and short-term deposits totaled USD 5.1 million at September 30, with projected runway through late 2027.
1. Quarterly results
Purple Biotech’s third-quarter 2026 net loss narrowed 25% year over year to USD 981,000, while research and development expenses fell 38% to USD 364,000, primarily due to lower manufacturing-related and patent expenses. The company had USD 5.1 million in cash, cash equivalents and short-term deposits at September 30, 2026, and projected runway through late 2027. It plans to submit an investigational new drug application for IM1240 during 2027, followed by a first-in-human study.




